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Abstract
Background: Intrapartum fetal hypoxia remains an important cause of death and permanent handicap and in a
significant proportion of cases there is evidence of suboptimal care related to fetal surveillance. Cardiotocographic
(CTG) monitoring remains the basis of intrapartum surveillance, but its interpretation by healthcare professionals
lacks reproducibility and the technology has not been shown to improve clinically important outcomes. The
addition of fetal electrocardiogram analysis has increased the potential to avoid adverse outcomes, but CTG
interpretation remains its main weakness. A program for computerised analysis of intrapartum fetal signals,
incorporating real-time alerts for healthcare professionals, has recently been developed. There is a need to
determine whether this technology can result in better perinatal outcomes.
Methods/design: This is a multicentre randomised clinical trial. Inclusion criteria are: women aged ≥ 16 years, able
to provide written informed consent, singleton pregnancies ≥ 36 weeks, cephalic presentation, no known major
fetal malformations, in labour but excluding active second stage, planned for continuous CTG monitoring, and no
known contra-indication for vaginal delivery. Eligible women will be randomised using a computer-generated
randomisation sequence to one of the two arms: continuous computer analysis of fetal monitoring signals with
real-time alerts (intervention arm) or continuous CTG monitoring as previously performed (control arm).
Electrocardiographic monitoring and fetal scalp blood sampling will be available in both arms. The primary
outcome measure is the incidence of fetal metabolic acidosis (umbilical artery pH < 7.05, BDecf > 12 mmol/L).
Secondary outcome measures are: caesarean section and instrumental vaginal delivery rates, use of fetal blood
sampling, 5-minute Apgar score < 7, neonatal intensive care unit admission, moderate and severe neonatal
encephalopathy with a marker of hypoxia, perinatal death, rate of internal monitoring, tracing quality, and signal
loss. Analysis will follow an intention to treat principle. Incidences of primary and secondary outcomes will be
compared between groups. Assuming a reduction in metabolic acidosis from 2.8% to 1.8%, using a two-sided test
with alpha = 0.05, power = 0.80, and 10% loss to follow-up, 8133 women need to be randomised.
Discussion: This study will provide evidence of the impact of intrapartum monitoring with computer analysis and
real-time alerts on the incidence of adverse perinatal outcomes, intrapartum interventions and signal quality.
(Current controlled trials ISRCTN42314164)
Background
Intrapartum complications accounted for 512 perinatal
deaths in the UK in 2004 [1] and remain an important
cause of long-term neurological morbidity and suffering
for families in industrialised countries [2]. In more than
half of such cases there is evidence of suboptimal care,
where different management would reasonably have been
expected to have made a difference to the outcome [3].
Problems related to fetal surveillance are the most com-
monly reported in these cases, and cardiotocograph
(CTG) interpretation is the basis for the most frequent
criticism [3].
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fetuses at risk of death or long-term injury caused by
decreased oxygen supply during labour. The majority of
cases of death and long-term disability are caused by
situations other than poor oxygenation during labour, so
to establish this diagnosis it is necessary to document
the occurrence of relevant changes in umbilical blood
gas values after birth. Umbilical artery metabolic acido-
sis has been associated with an increased risk of neuro-
logical injury [4], and is commonly used as a proxy
measure for adverse clinical outcome in this setting.
CTG monitoring remains the basis of intrapartum
fetal surveillance in high-risk cases and is applied on a
wide scale in industrialised countries, but its interpreta-
tion by health professionals has a well documented poor
reproducibility [5,6], and the technology has not been
shown to improve the most important clinical outcomes,
but rather to increase operative delivery rates [7]. Fetal
blood sampling (FBS) can be used in addition to CTG,
but it is invasive and time consuming, and only provides
time-limited information, all of which have limited its
application on a wide scale [8].
The addition of fetal electrocardiogram ST waveform
analysis to conventional CTG (STAN®, Neoventa,
Gothenburg, Sweden) has been shown to increase the
identification of fetuses with metabolic acidosis [9]. A
systematic review of the first three trials comparing
CTG+ST monitoring with conventional CTG showed
that the former significantly decreases the rates of fetal
blood sampling, neonatal encephalopathy and operative
delivery, and is associated with a borderline reduction in
the incidence of umbilical artery metabolic acidosis [10].
It has recently been documented that adverse neonatal
outcomes continue to occur with routine use of the
STAN® technology, because of human errors, such as
poor CTG interpretation, delay in taking appropriate
action, or failure to follow clinical guidelines [11], as
well as non-occurrence or very late occurrence of ST
events [12]. There is now a consensus among STAN®
users that visual interpretation of the CTG remains the
main weakness of the technology [13].
The Omniview-SisPorto® 3.5 program (Speculum, Lis-
bon, Portugal) provides computer analysis of both CTG
and ST signals, incorporating the concept of centralised
viewing of tracings on multiple stations and real-time
alerts for healthcare professionals [14]. The system has
been shown to provide analysis of CTG events that is in
good agreement with a consensus of experts [15] and
the program’s alerts have been shown to be highly pre-
dictive of fetuses born with severe acidemia [16], so it
has the potential to overcome some of the weaknesses
associated with human interpretation of the CTG. There
is now a need to determine whether the use of this
technology will result in improved perinatal outcomes.
Aims
The primary aim of the study is to determine whether
computer analysis of intrapartum fetal monitoring sig-
nals with real-time alerts (Omniview-SisPorto® 3.5) will
reduce the rate of umbilical artery metabolic acidosis
compared to continuous electronic fetal monitoring as
previously performed. Secondary aims are to quantify
other measures of perinatal outcome, intervention rates
and signal quality measures in both arms of the study.
The rationale for the main hypothesis of the study is
that real-time alerts are expected to prompt healthcare
professionals to identify, and act on changes that would
otherwise remain unnoticed. The technology may also
reduced human errors associated with inappropriate
CTG interpretation, including lack of identification of
cases showing reduced fetal heart rate variability [12].
Observational data suggest that the validity of compu-
terised intrapartum fetal monitoring provides additional
advantages [16].
Written informed consent for enrolment will be
requested from all participants. The trial is registered at
Current Controlled Trials with the number
ISRCTN42314164. The study protocol was approved by
the Cambridgeshire 1 Research Ethics Committee (REC
reference number 09/H0304/61)
Methods/design
Study Design and Setting
This is a pragmatic multicentre randomised clinical trial,
to be carried out in five United Kingdom hospitals,
including three tertiary teaching units and two district
general hospitals, all with high-risk women in labour.
Population and Methods
Participants/Eligibility criteria
Women will be eligible for participation if they fulfil the
following criteria:
￿ singleton pregnancy with cephalic presentation
￿ gestation ≥ 36 completed weeks
￿ no known major fetal malformations
￿ in active labour but not in active second stage
￿ no known contra-indication to vaginal delivery
￿ clinical decision made to perform continuous CTG
monitoring
Patients will not be included if they are under 16 years
of age, or are not able to provide written informed
consent.
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Patient study information (posters and leaflets) will be
distributed to eligible women on their initial contact
with healthcare professionals, and revisited during
antenatal and parentcraft classes, which take place at
different stages of pregnancy. The same information will
also be available to women on arrival in labour at parti-
cipating hospitals.
Consent request and enrolment
Eligible women will be asked by their attending midwife
whether they wish to participate when the clinical decision
is made to perform continuous fetal monitoring during
labour. The indication for instituting monitoring will be
recorded. If receptive, they will be asked for written
informed consent and subsequently enrolled in the trial, in
a window that is automatically opened by the Omniview-
SisPorto® 3.5 program. If enrolment does not take place,
the occurrence of exclusion criteria or the reasons
reported by women for not participating will be registered.
Randomisation
After enrolment, women will be randomised to one of
two arms using a 1:1 computer-generated randomisation
sequence attributed to each centre by the Omniview-
SisPorto® 3.5 program.
Intervention arm
Women randomised to the intervention arm will have
continuous fetal monitoring during labour with compu-
ter analysis by the Omniview-SisPorto® 3.5 program,
with real-time alerts to changes detected on CTG and/
or ST signals [14]. In this arm, ultimate management
decisions remain the responsibility of healthcare profes-
sionals, according to their best clinical judgment. This
may include CTG+ST analysis and/or FBS. However,
non-directive guidelines are provided to help understand
the meaning of the various alerts (Table 1).
Control arm
Women randomised to the control arm will have con-
tinuous fetal monitoring during labour without compu-
ter analysis or alerts, and will be managed according to
the centre’s existing guidelines. This may include ST
analysis and/or FBS as adjuncts to standard CTG.
Umbilical cord blood analysis
All enrolled cases will be subject to immediate double
cord clamping and paired cord blood sampling (umbili-
cal artery and vein), which are prerequisites for accurate
diagnosis of metabolic acidosis. Sampling into two pre-
heparinised syringes should be delayed by no more than
30 minutes, air bubbles will be removed, the syringes
capped, and blood analysis will occur in less than 30
minutes [17].
Collection of baseline, labour and outcome data
Baseline, labour and outcome data will be obtained by
the local research midwife on the next working day after
delivery and entered into the Omniview-SisPorto® 3.5
program. Baseline demographic and obstetric data of
enrolled women will include maternal age, height,
weight; pre-existing or current medical conditions; third
trimester group B streptococcus carrier state if known,
number of previous pregnancies; number of previous
vaginal, instrumental, and caesarean deliveries. Data on
the current labour will include gestational age; sponta-
neous or induced; normal or augmented; presence of
slight or thick meconium staining of amniotic fluid;
occurrence of fever (temp ≥38°C); use of epidural, par-
enteral, or inhaled analgesia; other intrapartum medica-
tions; result(s) of FBS; date and time of birth; interval
between end of fetal monitoring and delivery; normal,
instrumental, or caesarean delivery; indication for instru-
mental or caesarean delivery. Outcome data will include
newborn birthweight, sex; 1 and 5-min Apgar scores;
umbilical artery pH (3 decimal places), pCO2, bicarbo-
nate, BEecf; umbilical vein pH (3 decimal places), pCO2,
bicarbonate, BEecf; neonatal intensive care unit admis-
sion and indication. These data will be transmitted in an
anonymised format to the co-ordinating centre. Cord
acid base data will be assessed for accuracy. If cord
blood samples are not available, neonatal data will be
used to asses the occurrence of metabolic acidosis.
Table 1 Non-directive guidelines used to help understand the meaning of the various alerts
Signal loss/maternal heart rate monitoring Consider re-positioning the Doppler probe, changing to internal FHR
monitoring, re-evaluating the scalp electrode connections, or changing the
electrode
ST signal loss Consider re-evaluating the scalp electrode connections or changing the
electrode
Tachysystole (excessive number of uterine contractions) Consider discontinuing/reducing oxytocin infusion or acute tocolysis
Yellow alerts (tracing characteristics that do not fulfil the criteria of
normality, but are not usually associated with significant fetal hypoxia)
Consider maintaining close monitoring and/or starting ST analysis if
available
Orange alerts (FHR+ST characteristics that may be associated with
some degree of fetal hypoxia)
Consider reversal of hypoxic causes if possible, maintaining close
monitoring, starting ST analysis if available, or performing FBS
Red alerts (FHR+ST characteristics that are likely to be associated with
fetal hypoxia)
Consider immediate reversal of causes of hypoxia if possible or immediate
delivery
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Cases with metabolic acidosis (umbilical artery pH <
7.05 and BEecf > 12 mmol/L), 5-min Apgar score < 7, or
neonatal intensive care unit admission will be further
investigated by the local research midwife to evaluate
whether: neonatal blood analysis was performed in the
first hour of life, and its results including lactate; neona-
tal encephalopathy of any grade occurred in the first 72
hours of life; death of the infant occurred in the first 28
days of life; other important neonatal complications
occurred in the first 7 days of life; brain ultrasound or
other imaging technologies were performed in the first
7 days of life, and their results. At the same time, ser-
ious adverse events (see data safety monitoring commit-
tee, below) will be sought and reported.
Primary outcome measure
The primary outcome measure of this study is the inci-
dence of fetal metabolic acidosis (defined as an umbilical
artery pH < 7.05, BDecf > 12 mmol/L). BDecf will be cal-
culated from pH and PCO2 values, according to the Sig-
gaard-Andersen acid-base algorithm [18]. Subgroup
analysis, by participating centre and by availability or
non-availability of ST analysis will be carried out.
Secondary outcome measures
The secondary outcomes are: overall rates of caesarean
section and of caesarean section for non-reassuring fetal
state; overall rates of instrumental vaginal delivery and
of instrumental vaginal delivery for non-reassuring fetal
state; fetal blood sampling rates; incidence of 5-minute
Apgar score < 7; need for neonatal intensive care unit
admission; incidence of moderate and severe neonatal
encephalopathy with a hypoxic marker; perinatal death;
rate of delayed interventions (interval between red alerts
- offline analysis in the control arm - and delivery in
metabolic acidosis cases); internal FHR monitoring
rates; tracing quality and signal loss.
Sample size
The sample size calculation is based on the primary
endpoint: a metabolic acidosis incidence of about 2.8%
can reasonably be assumed, as this was previously
reported in an observational study conducted in one of
the participating centres [11]. Since this will be the first
trial to evaluate the effect of computer analysis of intra-
partum fetal monitoring signals and real-time alerts on
perinatal outcomes, it is not possible to find an estimate
of the degree of change that is expected. The closest
available parallel is the evaluation of STAN® monitoring
versus conventional CTG during labour. A systematic
review of the first three trials that studied this issue
revealed an overall relative risk for metabolic acidosis of
0.64. In the absence of a better alternative, this will be
the value used for initial sample size calculation. Thus
assuming a reduction in metabolic acidosis from 2.8% to
1.8%, with an alpha of 0.05, a two-sided test, and a
power of 0.80, about 7320 women will need to be ran-
domised. Accounting for a 10% loss to follow-up, the
study requires the inclusion of 8133 women in order to
obtain the 7320 analysable cases (3660 per arm). A pilot
analysis will be conducted after enrolment of the first
1500 cases to evaluate the real incidence of metabolic
acidosis, the effect of real-time alerts on its rate, and the
need to recalculate the trial’s sample size.
Data analysis
Data analysis will be carried out at the co-ordinating
centre and analysis of the primary endpoint will follow
the intention to treat principle. Minimal differences
between groups are expected in baseline patient charac-
teristics. The incidence of metabolic acidosis will be
compared across both groups, using relative risk with
95% confidence intervals. A similar methodology will be
applied to secondary outcomes.
Missing data
A case will be classified as having metabolic acidosis if it
falls within the described diagnostic criteria and the
arterial sample shows a pH value at least 0.03 units
lower and a PCO2 value at least 1 kPa higher than the
venous sample [18,17]. If these two latter criteria are
not met, or only one sample is available, it will be con-
sidered as indicating a venous sample. Venous samples
will still be considered for the diagnosis of metabolic
acidosis if they meet the diagnostic criteria. If no cord
blood acid base data is available, the case may still be
classified as having metabolic acidosis if the neonate has
acid-base data obtained in the first hour of life that fulfil
the diagnostic criteria, or if a lactate value greater than
10 mmol/L is documented in association with signs of
maladaptation (RDS, need for buffering etc).
Local Research Co-ordinators and Local Research
Midwifes
Ar e s e a r c hc o - o r d i n a t o ri ne a c hc e n t r ew i l lb er e s p o n s i -
ble for planning of the trial and for dissemination of
information to staff. A local research midwife will con-
tribute to these tasks, and be responsible for dissemina-
tion of information to possible participants, encouraging
high levels of patient recruitment, regular and timely
collection and recording of data, and provision of regu-
lar feedback to the co-ordinating centre on study pro-
gress and potential protocol violations.
Ethical Considerations
Written informed consent from all participants will be
obtained before trial enrolment. This is the first time
that computer analysis of intrapartum fetal monitoring
with real-time alerts is being compared with conven-
tional fetal monitoring in a randomised trial, so there is
no prior evidence of benefit for the reduction in the
incidence of adverse neonatal outcomes. However, there
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of fetal monitoring signals has a higher validity in pre-
diction of adverse outcomes [16].
T h ec o n f i d e n t i a l i t yo fp e r s o n a ld a t ai sg u a r a n t e e db y
the fact that person-identifiable data will not be avail-
able to anyone outside the local healthcare team. All
data transmitted to the co-ordinating centre will be
anonymised automatically.
Independent Data Safety Monitoring Committee
All serious adverse events (see below) will be reported
to the Data Safety Monitoring Committee, who will
evaluate their frequency regularly and determine
whether there is a significantly increased incidence in
the intervention group and if so, whether the study
should be discontinued.
This committee will consist of a neonatologist, an
obstetrician, and a statistician. Serious adverse events
are defined as any of the following:
￿ severe metabolic acidosis (umbilical artery pH < 7.00
and BEecf > 12 mmol/L) and neonatal intensive care
unit admission
￿ 5-min Apgar score < 7 and neonatal intensive care
unit admission
￿ First available pH value after birth < 7.05 or first
available lactate value after birth > 10 mmol/L
￿ Grade II or III neonatal encephalopathy
￿ Death in the first 28 days of life
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